rovelizumab   Click here for help

GtoPdb Ligand ID: 9598

Synonyms: Hu23F2G | LeukArrest
Immunopharmacology Ligand
Compound class: Antibody
Comment: Rovelizumab (Hu23F2G) is a humanized IgG4 bispecific monoclonal antibody targeting integrin alpha L subunit (ITGAL, CD11A) and integrin beta 2 subunit (ITGB2, CD18) [5], which are components of the leukocyte adhesion integrin LFA-1. Rovelizumab was developed by Icos Corporation (later acquired by Eli Lilly) for potential use in multiple sclerosis, myocardial infarction and ischemic stroke.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
integrin, alpha L subunit (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) Primary target of this compound Hs Antibody Binding - - - 2,5
⤷ [2,5]
integrin, beta 2 subunit (complement component 3 receptor 3 and 4 subunit) Primary target of this compound Hs Antibody Binding - - - 2,5
⤷ [2,5]